Market Overview
The global anti-vascular endothelial growth factor (anti-VEGF) therapeutics market was valued at USD 12.09 billion in 2021 and is expected to grow at a CAGR of 0.4% during the forecast period. Anti-VEGF therapies are designed to inhibit the action of vascular endothelial growth factors, which play a crucial role in the formation of new blood vessels (angiogenesis). These therapies are widely used for treating various diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers.
The increasing prevalence of chronic eye disorders, a growing elderly population, and rising incidences of cancer are key factors driving the market. Moreover, technological advancements in biologics and an expanding pipeline of biosimilars contribute to the market’s resilience, even with a moderate growth rate.
Market Segmentation
- By Therapy Type
- Monoclonal Antibodies
Monoclonal antibodies such as bevacizumab (Avastin) dominate the market due to their effectiveness in cancer and ophthalmic treatments. - Biosimilars
The launch and adoption of biosimilars have provided more affordable options, thus widening patient access and influencing market dynamics. - Fusion Proteins
Fusion proteins offer innovative treatment options and are gaining ground for specific ophthalmologic applications. - By Indication
- Oncology
Anti-VEGF therapies are extensively used in cancer treatments to inhibit tumor growth by preventing angiogenesis. - Ophthalmology
Conditions such as AMD, diabetic macular edema, and retinal vein occlusion are primary areas where anti-VEGF therapies are deployed. - Others
Research into new indications for anti-VEGF therapies continues to expand, including applications in respiratory and inflammatory diseases. - By Distribution Channel
- Hospital Pharmacies
Hospital pharmacies remain the primary distribution channel, catering to large patient pools and specialized treatment facilities. - Retail Pharmacies
Retail pharmacies are increasingly providing access to injectable anti-VEGF therapies, especially for chronic conditions. - Online Pharmacies
The rise of online pharmacies has improved drug accessibility, particularly for maintenance therapies in ophthalmology.
Regional Analysis
- North America
North America holds the largest market share, driven by advanced healthcare infrastructure, a high prevalence of chronic diseases, and strong research and development activities. - Europe
Europe follows closely, with strong adoption rates of anti-VEGF biosimilars and government support for innovative biologic therapies. - Asia-Pacific
Asia-Pacific is projected to witness significant growth, fueled by a rising elderly population, increased healthcare spending, and improving access to specialized treatments. - Latin America
Latin America is experiencing steady growth due to a gradual improvement in healthcare systems and increasing awareness of available treatment options. - Middle East & Africa
Though currently a smaller market, the Middle East & Africa region is expected to show promising growth due to rising healthcare investments and an increasing focus on non-communicable diseases.
Key Companies in the Anti-Vascular Endothelial Growth Factor Therapeutics Market
Major companies operating in the global anti-VEGF therapeutics market include:
- Amgen Inc.
- Bausch Health Companies Inc.
- Coherus Biosciences
- Eli Lilly
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- Pfizer Inc.
- Viatris Inc.
- Xbrane Biopharma AB
These companies are actively focusing on expanding their therapeutic portfolios, investing in biosimilar development, and engaging in strategic collaborations to strengthen their market position.
Growth Drivers and Challenges
The primary drivers for market growth include the increasing burden of ophthalmologic and oncologic diseases and technological advancements in biologics manufacturing. Additionally, the emergence of biosimilars is expected to make anti-VEGF treatments more accessible to broader patient populations.
However, challenges such as high treatment costs, stringent regulatory approvals, and competition from alternative therapies could restrict market growth. Furthermore, patient adherence to injectable therapies in ophthalmology remains a notable concern for healthcare providers.
Conclusion
Despite a modest growth rate, the anti-vascular endothelial growth factor therapeutics market remains vital due to its critical role in treating severe and prevalent diseases like cancer and AMD. Innovations in biosimilars, expanding indications, and rising global disease burden ensure that key players such as Amgen Inc., Roche, Genentech, and Pfizer will continue to drive the market forward.
With the market expected to reach approximately USD 12.59 billion by 2034, stakeholders in the anti-VEGF space are poised to benefit from targeted investment in research, development, and patient-centric strategies.
More Trending Latest Reports By Polaris Market Research:
Healthcare Cybersecurity Market
Transdermal Drug Delivery Systems Market
Artificial Intelligence (AI) in Mental Health Market